NanoVibronix Inc (NAOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NanoVibronix Inc (NAOV) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.97 Million) by net assets ($42.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of NanoVibronix Inc to measure how much of total assets are equity-financed.
NanoVibronix Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how NanoVibronix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is NanoVibronix Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
NanoVibronix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoVibronix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Innity Corporation Bhd
KLSE:0147
|
-0.154x |
|
Aino Health AB
ST:AINO
|
0.211x |
|
Trucknet Enterprise Ltd
TA:TRAN
|
N/A |
|
Blockmate Ventures Inc
V:MATE
|
0.102x |
|
CPPGroup Plc
F:4CV1
|
-2.851x |
|
Moho Resources Ltd
AU:MOH
|
-0.204x |
|
Mittal Life Style Limited
NSE:MITTAL
|
0.102x |
|
Chrysalis Investments Ltd
LSE:CHRY
|
-0.006x |
Annual Cash Flow Conversion Efficiency for NanoVibronix Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of NanoVibronix Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see NanoVibronix Inc (NAOV) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $627.00K | $-2.52 Million | -4.013x | -344.28% |
| 2023-12-31 | $3.99 Million | $-3.60 Million | -0.903x | +58.49% |
| 2022-12-31 | $3.23 Million | $-7.04 Million | -2.176x | -214.57% |
| 2021-12-31 | $6.31 Million | $-4.37 Million | -0.692x | +51.16% |
| 2020-12-31 | $2.39 Million | $-3.39 Million | -1.416x | +50.71% |
| 2019-12-31 | $1.35 Million | $-3.87 Million | -2.874x | +62.52% |
| 2018-12-31 | $463.00K | $-3.55 Million | -7.667x | -1176.96% |
| 2017-12-31 | $3.63 Million | $-2.18 Million | -0.600x | -197.88% |
| 2016-12-31 | $-2.50 Million | $-1.53 Million | 0.613x | -91.34% |
| 2015-12-31 | $-209.00K | $-1.48 Million | 7.081x | +4318.76% |
| 2014-12-31 | $-5.62 Million | $-900.00K | 0.160x | -12.23% |
| 2013-12-31 | $-3.30 Million | $-602.00K | 0.183x | -57.50% |
| 2012-12-31 | $-1.83 Million | $-787.00K | 0.430x | -54.06% |
| 2011-12-31 | $-585.00K | $-547.00K | 0.935x | -- |
About NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more